Holen Sie sich die Stockscreener-App
17.09
6.97%
-1.28
Handel nachbörslich:
17.09
Schlusskurs vom Vortag:
$18.37
Offen:
$17.81
24-Stunden-Volumen:
2.88M
Relative Volume:
2.08
Marktkapitalisierung:
$3.19B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-323.01M
KGV:
-7.6982
EPS:
-2.22
Netto-Cashflow:
$-272.30M
1W Leistung:
-12.09%
1M Leistung:
-17.04%
6M Leistung:
-40.06%
1J Leistung:
-47.11%
1-Tages-Spanne:
$16.72
$17.81
1-Wochen-Bereich:
$16.72
$19.39
52-Wochen-Spanne:
$16.72
$34.47
Immunovant Inc Stock (IMVT) Company Profile
Firmenname
Immunovant Inc
Sektor
Branche
Telefon
917-580-3099
Adresse
320 WEST 37TH STREET, NEW YORK, NY
Vergleichen Sie IMVT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
17.09 | 3.19B | 0 | -323.01M | -272.30M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-03 | Eingeleitet | Jefferies | Hold |
| 2025-01-03 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-10-09 | Bestätigt | Oppenheimer | Outperform |
| 2024-03-28 | Eingeleitet | Oppenheimer | Outperform |
| 2024-03-13 | Eingeleitet | Goldman | Buy |
| 2024-02-20 | Eingeleitet | JP Morgan | Overweight |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-13 | Hochstufung | UBS | Neutral → Buy |
| 2023-09-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | Eingeleitet | BofA Securities | Buy |
| 2023-04-25 | Eingeleitet | Citigroup | Buy |
| 2023-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2023-03-30 | Eingeleitet | Stifel | Buy |
| 2023-02-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-01-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | Herabstufung | UBS | Buy → Neutral |
| 2021-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-08-03 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-06-01 | Herabstufung | Stifel | Buy → Hold |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-10-12 | Eingeleitet | Guggenheim | Buy |
| 2020-10-08 | Eingeleitet | Stifel | Buy |
| 2020-10-02 | Eingeleitet | Credit Suisse | Outperform |
| 2020-08-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-07-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-24 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Immunovant Inc Aktie (IMVT) Neueste Nachrichten
Swiss National Bank Grows Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Batoclimab eases disease severity; Immunovant backs IMVT-1402 - Myasthenia Gravis News
Teenager dies after receiving Sarepta therapy; Immunovant gets Phase 3 win, but shifts focus; Alnylam’s big moment; and more - Endpoints News
Charles Schwab Investment Management Inc. Increases Holdings in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Bank of America Has Lowered Expectations for Immunovant (NASDAQ:IMVT) Stock Price - Defense World
Immunovant (NASDAQ:IMVT) Earns Buy Rating from Guggenheim - Defense World
Immunovant price target raised to $61 from $58 at Stifel - Yahoo Finance
Long Term Trading Analysis for (IMVT) - news.stocktradersdaily.com
HC Wainwright Reiterates “Buy” Rating for Immunovant (NASDAQ:IMVT) - Defense World
Immunovant stock hits 52-week low at $17.15 amid market challenges - Investing.com Australia
Stifel raises Immunovant stock price target to $61 from $58 By Investing.com - Investing.com Canada
Street View: Immunovant's muscle drug shows potential as analysts await data on lead candidate - TradingView
Immunovant’s batoclimab shows ‘impressive’ efficacy in MG, says H.C. Wainwright - Yahoo Finance
IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success - TradingView
Immunovant stock holds $51 target on positive trial data By Investing.com - Investing.com Canada
Immunovant, Inc. (NASDAQ:IMVT) Shares Sold by Victory Capital Management Inc. - Defense World
Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward (IMVT) - Seeking Alpha
Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data - AOL
Immunovant’s Batoclimab Shows Promising Efficacy in MG and CIDP, Justifying Buy Rating - TipRanks
Immunovant will not seek approval for MG therapy, despite hitting endpoints - Yahoo Finance
Immunovant's muscle drug meets main goal, shares gain on new drug promise - Reuters.com
Immunovant claims study success for immune disease drug but holds off on submission - BioPharma Dive
Immunovant Will Drop One Myasthenia Gravis Asset, Continuing to Favor Another - BioSpace
Immunovant stock hits 52-week low at $17.15 amid market challenges By Investing.com - Investing.com South Africa
Positive batoclimab data from Immunovant, but doubts raised on further development - The Pharma Letter
En garde, Vyvgart: Immunovant rolls out MG data - BioWorld MedTech
Immunovant's muscle drug data underwhelms, shares gain on new drug promise -March 19, 2025 at 08:12 am EDT - Marketscreener.com
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT) - PR Newswire
Immunovant stock Roivant stock slip on trial data (IMVT) - Seeking Alpha
Immunovant Says Currently Not Planning to Seek Approval of Batoclimab for Myasthenia Gravis; Shares Drop Pre-Bell - Marketscreener.com
Immunovant reports promising Phase 3 MG study results - Investing.com India
Roivant Sciences Announces Positive Results for Batoclimab Studies - TipRanks
Immunovant's muscle disorder treatment meets main goal in late-stage trial -March 19, 2025 at 08:12 am EDT - Marketscreener.com
Immunovant stock falls despite study success By Investing.com - Investing.com South Africa
Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies - The Manila Times
Immunovant stock falls despite study success - Investing.com
Immunovant's muscle disorder treatment meets main goal in late-stage trial -March 19, 2025 at 07:52 am EDT - MarketScreener
Immunovant reports promising Phase 3 MG study results By Investing.com - Investing.com UK
Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs - The Manila Times
Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs - The Manila Times
Immunovant, Inc. to Host Investor Webcast on Phase 3 Study Results of Batoclimab in MG and Phase 2b Study in CIDP - Nasdaq
Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from - The Bakersfield Californian
Critical Phase 3 Results: Immunovant's Breakthrough MG and CIDP Treatment Data Reveal Coming Next Week - StockTitan
What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday? - AOL
Immunovant director Andrew Fromkin sells $156,768 in stock By Investing.com - Investing.com Australia
Immunovant director Andrew Fromkin sells $156,768 in stock - Investing.com India
Immunovant’s (IMVT) Buy Rating Reaffirmed at Guggenheim - Defense World
(IMVT) Investment Report - Stock Traders Daily
Commit To Buy Immunovant At $15, Earn 15.1% Annualized Using Options - Nasdaq
Cantor Fitzgerald Estimates Immunovant FY2025 Earnings - Defense World
Brokerages Set Immunovant, Inc. (NASDAQ:IMVT) PT at $43.55 - Defense World
Finanzdaten der Immunovant Inc-Aktie (IMVT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.05%
1.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):